US2004219637A1PendingUtilityA1
Soluble recombinant botulinum toxins having a C-terminal portion of a heavy chain, a N-terminal portion of a heavy chain and a light chain
Assignee: ALLERGAN SALES INC ALLERGAN BOPriority: Mar 16, 1995Filed: Dec 5, 2003Published: Nov 4, 2004
Est. expiryMar 16, 2015(expired)· nominal 20-yr term from priority
Inventors:James A. Williams
A61K 39/00A61K 2039/505C07K 16/1282C07K 14/33C07K 16/02C07K 14/245Y02A50/30C07K 2317/34C07K 2319/00
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
Claims
exact text as granted — not AI-modified1 - 24 . (canceled)
25 . A recombinant botulinum toxin comprising a soluble C-terminal portion of a botulinum toxin heavy chain, an N-terminal portion of a botulinum toxin heavy chain and a botulinum toxin light chain 25 wherein the C-terminal portion comprises SEQ ID NO: 23 and the N-terminal portion and the light chain each comprise a portion of SEQ ID NO: 28.
26 . The recombinant toxin of claim 25 further comprising a non-toxin protein sequence.
27 . The recombinant toxin of claim 25 wherein the toxin is in a solution.
28 . The recombinant botulinum toxin of claim 25 wherein the light chain is solubilized.
29 . The recombinant toxin of claim 25 wherein the C-terminal portion and the N-terminal portion are bonded together.
30 . The recombinant toxin of claim 29 wherein the bond is a covalent bond.
31 . The recombinant toxin of claim 25 wherein the light chain is bonded to the C-terminal portion or the N-terminal portion.
32 . A recombinant botulinum toxin comprising a soluble C-terminal portion of a botulinum toxin type A heavy chain, an N-terminal portion of a botulinum toxin type A heavy chain and a botulinum toxin type A light chain wherein the C-terminal portion comprises SEQ ID NO: 23 and the N-terminal portion and the light chain each comprise a portion of SEQ ID NO: 28.
33 . The recombinant toxin of claim 32 further comprising a non-toxin protein sequence.
34 . The recombinant toxin of claim 32 wherein the toxin is in a solution.
35 . The recombinant botulinum toxin of claim 32 wherein the light chain is solubilized.
36 . The recombinant toxin of claim 32 wherein the C-terminal portion and the N-terminal portion are bonded together.
37 . The recombinant toxin of claim 36 wherein the bond is a covalent bond.
38 . The recombinant toxin of claim 32 wherein the light chain is bonded to the C-terminal portion or the N-terminal portion.Join the waitlist — get patent alerts
Track US2004219637A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.